AstraZeneca Ramps Up U.S. Sales Force Before Nexium, Statin Launches
Executive Summary
AstraZeneca plans to hire more in-house sales reps and decrease its "substantial reliance on contract sales organizations," Senior VP-Commercialization and Portfolio Management David Brennan said at the company's half-year results presentation in London Aug. 1.
You may also be interested in...
AstraZeneca Faslodex Is First Launch For Doubled Oncology Sales Force
AstraZeneca's Faslodex is the first launch to be detailed by the company's recently-expanded oncology sales force, following FDA approval of the estrogen receptor down-regulator April 25
AstraZeneca Faslodex Is First Launch For Doubled Oncology Sales Force
AstraZeneca's Faslodex is the first launch to be detailed by the company's recently-expanded oncology sales force, following FDA approval of the estrogen receptor down-regulator April 25
AstraZeneca Prilosec OTC Prevention Claim Up For Committee Review Oct. 20
AstraZeneca is seeking a prevention claim for an over-the-counter version of its proton pump inhibitor Prilosec (omeprazole).